Invesco
NMRA icon

Invesco’s Neumora Therapeutics NMRA Stock Holding History

Invesco’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$413K Buy
243,195
+37,266
+18% +$70.9K ﹤0.01% 3316
2026
Q1 		$402K Sell
205,929
-21,665
-10% -$56.1K ﹤0.01% 3242
2025
Q4 		$407K Buy
227,594
+43,795
+24% +$95.9K ﹤0.01% 3279
2025
Q3 		$335K Buy
183,799
+51,761
+39% +$83.7K ﹤0.01% 3379
2025
Q2 		$96.8K Buy
132,038
+8,383
+7% +$6.35K ﹤0.01% 3657
2025
Q1 		$124K Buy
123,655
+74,406
+151% +$127K ﹤0.01% 3600
2024
Q4 		$522K Buy
49,249
+35,342
+254% +$424K ﹤0.01% 3221
2024
Q3 		$184K Buy
13,907
+462
+3% +$5.39K ﹤0.01% 3532
2024
Q2 		$132K Buy
+13,445
New +$139K ﹤0.01% 3716

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Invesco's NMRA Position: Q2 2026 in Review

Invesco increased its Neumora Therapeutics (NMRA) stake by 18% in Q2 2026, buying an estimated $70.9K and bringing the position to 243,195 shares worth $413K. The position accounts for ﹤0.01% of the portfolio, ranked #3316.

Invesco first reported a position in NMRA in Q2 2024 and has held it in 9 quarters since. The position peaked at $522K in Q4 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Invesco held 243,195 shares of Neumora Therapeutics worth $413K as of Q2 2026.
  • Invesco bought 37,266 Neumora Therapeutics shares in Q2 2026, an estimated $70.9K.
  • Neumora Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3316 holding.
  • Invesco first reported a position in Neumora Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Invesco's Neumora Therapeutics position peaked at $522K in Q4 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.